Mirum Pharmaceuticals, Inc.

NasdaqGM MIRM

Mirum Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -97.30 M

Mirum Pharmaceuticals, Inc. Net Income is USD -97.30 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 40.74% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Mirum Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -164.19 M, a -293.85% change year over year.
Mirum Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -41.69 M, a 76.68% change year over year.
Mirum Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -178.74 M, a -112.73% change year over year.
Mirum Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -84.02 M, a -38.77% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGM: MIRM

Mirum Pharmaceuticals, Inc.

CEO	Mr. Christopher Peetz
IPO Date	July 18, 2019
Location	United States
Headquarters	950 Tower Lane
Employees	311
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Key trends

Past 5 years